The effects of candidate probiotic strains on the gut environment in dextran sulfate sodium-induced colitis mouse
Rattachement africain : kr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Inflammatory bowel disease (IBD) is a chronic condition characterized by intestinal inflammation and dysbiosis, with limited treatment options and significant challenges in long-term management. This study investigated the therapeutic potential of novel strains belonging to Bifidobacterium longum and Limosilactobacillus species, in a dextran sodium sulfate (DSS)-induced mouse model of colitis. In this study, our primary objective was to determine whether ingestion of these strains alleviates colitis symptoms and, if so, to elucidate how they restored gut microbial balance and modulated microbial metabolic functions. In most probiotic-treated groups, colitis disease activity index scores were significantly improved and colon length was preserved, with strains CBA7106 and BBH exhibiting efficacy comparable to that of the Lactobacillus rhamnosus GG (used as a positive control). Moreover, histological analyses confirmed reduced inflammation and enhanced mucosal integrity. Microbial diversity assessments demonstrated a marked restoration of gut microbial composition, highlighted by increased abundances of beneficial taxa such as Lactobacillus and Akkermansia. Metabolomic profiling identified key anti-inflammatory metabolites, including 6-hydroxycaproic acid, indole-3-lactic acid, and choline, which were significantly elevated in the probiotic-treated groups. Notably, functional analyses using PICRUSt2 revealed a sustained decrease in the siderophore biosynthesis pathway (ko01053), suggesting that these candidate probiotic strains may inhibit siderophore production-a pivotal mechanism by which pathogenic bacteria aggravate intestinal inflammation. Taken together, these findings indicate that the candidate probiotic strains CBA7106 and BBH effectively mitigate DSS-induced colitis by modulating the gut microbiota, promoting the production of anti-inflammatory metabolites, and suppressing siderophore biosynthesis. This study provides valuable insights into the development of targeted probiotic therapies for IBD, underscoring their potential as a complementary approach to restoring intestinal health and reducing inflammation. Further clinical studies are warranted to validate these observations in human populations.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The effects of candidate probiotic strains on the gut environment in dextran sulfate sodium-induced colitis mouse
- Date Crossref
- 01/07/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Helixmith (South Korea) pays non établi dans la noticeEntreprise
-
Gyeongsang National University Research Institute of Pharmaceutical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Dankook University Center for Bio-Medical Engineering Core Facility pays non établi dans la noticeUniversité ou école supérieure
-
Pusan National University pays non établi dans la noticeUniversité ou école supérieure
-
Seoul National University Department of Agricultural Biotechnology pays non établi dans la noticeUniversité ou école supérieure
-
Korea Food Research Institute Precision Nutrition Research Group pays non établi dans la noticeStructure de recherche
-
Ltd HuNBiome Co. pays non établi dans la noticeEntreprise
-
College of Science & Technology pays non établi dans la noticeUniversité ou école supérieure
-
Wonkwang Digestive Disease Research Institute pays non établi dans la noticeStructure de recherche
-
College of Pharmacy Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Seongnam BioBankHealing pays non établi dans la noticeOrganisation à but non lucratif
Helixmith (South Korea), Research Institute of Pharmaceutical Sciences — Gyeongsang National University et Center for Bio-Medical Engineering Core Facility — Dankook University, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.